The present application relates to the technical field of mRNA vaccine, and specifically discloses a
proinsulin mRNA vaccine for protecting the function and quantity of
pancreatic beta cells. The vaccine is composed of a lipid
nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding
proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of
pancreatic beta cells, compared with the existing intervention means which only focus on blood
glucose control or
immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and
drug selection for the prevention and early intervention of type 1 diabetes.